Ki Hyun Bae
Overview
Explore the profile of Ki Hyun Bae including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
884
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maniyamgama N, Bae K, Chang Z, Lee J, Ang M, Tan Y, et al.
Adv Sci (Weinh)
. 2025 Jan;
:e2407383.
PMID: 39888252
Intranasal delivery of mRNA vaccines offers promising opportunities to combat airborne viruses like SARS-CoV-2 by provoking mucosal immunity, which not only defends against respiratory infection but also prevents contagious transmission....
2.
Zhang L, Seow B, Ba K, Bae K, Zhang Y, Liao K, et al.
J Control Release
. 2025 Jan;
380:108-124.
PMID: 39875076
mRNA-loaded lipid nanoparticles (mRNA-LNPs) hold great potential for disease treatment and prevention. LNPs are normally made from four lipids including ionizable lipid, helper lipid, cholesterol, and PEGylated lipid (PEG-lipid). Although...
3.
Benetti A, Tan E, Chang Z, Bae K, Thwin M, Muthuramalingam R, et al.
Vaccines (Basel)
. 2024 Apr;
12(4).
PMID: 38675792
Chitosan, a natural polysaccharide derived from chitin, possesses biocompatibility, biodegradability, and mucoadhesive characteristics, making it an attractive material for the delivery of mRNA payloads to the nasal mucosa and promoting...
4.
Liau B, Zhang L, Ang M, Ng J, C V S, Schneider S, et al.
Nanomedicine
. 2024 Mar;
58:102745.
PMID: 38499167
Understanding the stability of mRNA loaded lipid nanoparticles (mRNA-LNPs) is imperative for their clinical development. Herein, we propose the use of size-exclusion chromatography coupled with dual-angle light scattering (SEC-MALS) as...
5.
Bae K, Shunmuganathan B, Zhang L, Lim A, Gupta R, Wang Y, et al.
NPJ Vaccines
. 2024 Feb;
9(1):43.
PMID: 38396073
The advent of SARS-CoV-2 variants with defined mutations that augment pathogenicity and/or increase immune evasiveness continues to stimulate global efforts to improve vaccine formulation and efficacy. The extraordinary advantages of...
6.
Bae K, Lai F, Chen Q, Kurisawa M
Polymers (Basel)
. 2024 Jan;
16(2).
PMID: 38257023
Acute myeloid leukemia carrying FMS-like tyrosine kinase receptor-3 (FLT3) mutations is a fatal blood cancer with a poor prognosis. Although the FLT3 inhibitor gilteritinib has recently been approved, it still...
7.
Lee G, Ko Y, Bae K, Kurisawa M, Kwon O, Kwon O
Biomater Res
. 2023 Sep;
27(1):94.
PMID: 37775835
No abstract available.
8.
Bae K, Lai F, Oruc B, Osato M, Chen Q, Kurisawa M
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613821
Chemoresistance is one of the major challenges for the treatment of acute myeloid leukemia. Epigallocatechin gallate (EGCG), a bioactive polyphenol from green tea, has attracted immense interest as a potential...
9.
Bae K, Lai F, Mong J, Niibori-Nambu A, Chan K, Her Z, et al.
J Nanobiotechnology
. 2022 Nov;
20(1):481.
PMID: 36384529
Background: Currently available anti-leukemia drugs have shown limited success in the treatment of acute myeloid leukemia (AML) due to their poor access to bone marrow niche supporting leukemic cell proliferation....
10.
Lee G, Ko Y, Bae K, Kurisawa M, Kwon O, Kwon O
Biomater Res
. 2022 Nov;
26(1):62.
PMID: 36352485
Background: Overproduction of reactive oxygen species (ROS) is known to delay wound healing by causing oxidative tissue damage and inflammation. The green tea catechin, (-)-Epigallocatechin-3-O-gallate (EGCG), has drawn a great...